CST, 79381S, ABT-263 (Navitoclax)

Chemical Modulators for studying in the research area. Product Usage Information ABT-263 (Navitoclax) is supplied as a lyophilized powder. For a 5 mM stock, reconstitute 5 mg of powder in 1.0 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect. Storage Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles. Background ABT-263 (Navitoclax) is a potent and orally bioavailable Bcl-2 family inhibitor. This small molecule mimetic of BH3 domains specifically binds to Bcl-2, Bcl-xL, and Bcl-W with a K value of less than 1 nM (1). ABT-263 (Navitoclax) has been shown to have antitumor effects on small cell lung cancer (SCLC) xenograft models, resulting in complete tumor regression in some cases (2). Studies have shown that ABT-263 (Navitoclax) can enhance the effectiveness of chemotherapeutic and targeted agents against solid tumors (3). ABT-263 (Navitoclax) induces apoptosis, particularly in certain types of senescent cells (4,5). Alternate Names (R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)- 3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]- phenyl]sulfonyl]-benzamide; 855071; ABT263; Navitoclax